Double attack: chemo and radioactive beads take on liver tumors

NCT ID NCT04339036

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two chemotherapy drugs (capecitabine and temozolomide) plus tiny radioactive beads delivered directly to the liver (Y90 radioembolization) in 70 people with grade 2 or 3 neuroendocrine tumors that have spread to the liver. The goal is to see if this approach keeps liver tumors from growing longer than either treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine (Xeloda), Temozolomide (Temodar), and Yttrium-90 radioembolization (Y90 beads)
What this could lead to: If successful, this combination could offer better control of liver tumors in people with neuroendocrine cancer that has spread to the liver.
What could go wrong: This is a mid-stage trial with only 70 participants, so results may not apply to everyone. The combination also carries risks like liver damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR GRADE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMOR GRADE 2 NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14203, United States
UC San Diego
RECRUITING

La Jolla, California, 92037, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
RECRUITING

Miami, Florida, 33136, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.